TRPV1 receptor antagonists - Pipeline Insight, 2024

This “TRPV1 receptor antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in TRPV1 receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

TRPV1 receptor antagonists Understanding

TRPV1 receptor antagonists: Overview

The transient receptor potential vanilloid 1 (TRPV1) ion channel is mainly found in primary nociceptive afferents whose activity has been linked to pathophysiological conditions including pain, itch and inflammation. The function of TRPV1 is detection and regulation of body temperature. In addition, TRPV1 provides a sensation of scalding heat and pain (nociception). In primary afferent sensory neurons, it cooperates with TRPA1 (a chemical irritant receptor) to mediate the detection of noxious environmental stimuli. Antagonists block TRPV1 activity, thus reducing pain. Identified antagonists include the competitive antagonist capsazepine and the non-competitive antagonist ruthenium red. These agents could be useful when applied systemically. Numerous TRPV1 antagonists have been developed by pharmaceutical companies. TRPV1 antagonists have shown efficacy in reducing nociception from inflammatory and neuropathic pain models in rats.

TRPV1 receptor antagonists - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the TRPV1 receptor antagonists pipeline landscape is provided which includes the disease overview and TRPV1 receptor antagonists treatment guidelines. The assessment part of the report embraces, in depth TRPV1 receptor antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, TRPV1 receptor antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence TRPV1 receptor antagonists R&D. The therapies under development are focused on novel approaches to treat/improve TRPV1 receptor antagonists.

TRPV1 receptor antagonists Emerging Drugs Chapters

This segment of the TRPV1 receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

TRPV1 receptor antagonists Emerging Drugs

Tivanisiran: Sylentics Tivanisiran is a chemically synthesized small interference RNA (si RNA) inhibitor of the Transient Receptor Potential Vanilloid-1 (TRPV1) formulated as eye drops. This receptor is a nociceptor that maintains a dual function in corneal tissues participating in pain sensing, transmission and regulation as well as acting as a mediator of innate inflammatory response. These actions make it an ideal candidate for treating DED. Tivanisiran belongs to a new emerging drug class whose mechanism of action differs from traditional small-molecules. It is being evaluated in Phase III stage of development for the treatment ofdryeyes.

TRPV1 receptor antagonists: Therapeutic Assessment

This segment of the report provides insights about the different TRPV1 receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in TRPV1 receptor antagonists

There are approx. 4+ key companies which are developing the therapies for TRPV1 receptor antagonists. The companies which have their TRPV1 receptor antagonists drug candidates in the most advanced stage, i.e. phase II include Sylentics.

Phases

This report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

TRPV1 receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

TRPV1 receptor antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TRPV1 receptor antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TRPV1 receptor antagonists drugs.

TRPV1 receptor antagonists Report Insights

• TRPV1 receptor antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

TRPV1 receptor antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing TRPV1 receptor antagonists drugs?
• How many TRPV1 receptor antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TRPV1 receptor antagonists?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the TRPV1 receptor antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for TRPV1 receptor antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 2 business days.